Understanding of the pathophysiology of retinopathy of prematurity (ROP) is needed to accurately identify at-risk infants and ensure timely screening. Schedules and strategies for ROP screening are geared toward the detection of vision-threatening ROP.
1. Understand pathophysiology and stages of retinopathy of prematurity (ROP) development.
2. Define US screening criteria for ROP and identify at-risk infants.
3. Define type 1 ROP, the ROP severity that warrants consideration of treatment.
4. Have an awareness of tools that aid in detecting at-risk infants and methods used to identify type 1 ROP. 
INTRODUCTION
Retinopathy of prematurity (ROP) is a retinal vascular disease found in premature infants, and was first described by Terry in 1942 as "retrolental fibroplasia" due to the appearance of a complete retinal detachment behind the lens. (1) Although many causes were investigated, it was not until the mid-1950s that a randomized multicenter trial showed a clear association between increased incidence of ROP and increased duration of exposure to oxygen. (2) Decades of research have helped optimize management of oxygen supplementation for premature infants, with goals to maximize survival but minimize complications of ROP, pulmonary disease, and other morbidities. Early studies did not show increased mortality in infants with oxygen curtailment or a relationship between ROP development and the concentration of oxygen administered; however, more recent studies found a higher mortality rate among infants given a lower target oxygen saturation range (85%-89% vs 91%-95% (14) VEGF is also potentiated by insulinlike growth factor 1 (IGF-1), which is deficient in infants born before completion of the third trimester of pregnancy. Optimum concentrations of VEGF and IGF-1 are crucial for normal growth and development of many tissues, including eyes, blood vessels, and brain. (15) The pathophysiology is important when considering management of clinical care with regard to ROP. Changes in clinical care might be implemented during the first phase, before ROP develops. Screening for ROP should coincide with the second phase, to detect ROP of the severity that can lead to visual disability. Mild ROP usually resolves spontaneously and without clinically significant visual or ocular sequelae, but more severe ROP must be detected before unfavorable anatomic changes occur. Some variability in the pace at which ROP develops has been described in at-risk infants and populations. Screening guidelines must incorporate risk factors for the development of ROP and the schedule for screening examinations must be modified based on findings and risks. The extent of disease is described in the number of clock hours of ROP (ranging from 1-12, interrupted or contiguous). Increased dilation and tortuosity of posterior retinal vessels is described as "plus disease," which is an ominous sign of active and progressive disease. More severe disease is characterized by higher stage of ROP in a lower zone of ROP and presence of plus disease. In the new classification, a more severe form of retinopathy found in extremely low birthweight infants (aggressive posterior ROP, formerly known as "rush disease") is described, which involves central flat intraretinal neovascularization with plus disease. Aggressive posterior ROP can progress very quickly to stage 5 ROP and blindness, so it must be recognized early. Poor vision typically results from ROP that causes macular distortion or detachment of the retina (including the macula), so detection and treatment is needed before this occurs.
CLASSIFICATION OF RETINOPATHY OF PREMATURITY
Current treatment recommendations are based on the findings from the ETROP study. (18) This study randomized eyes with high-risk prethreshold ROP to receive treatment earlier than or at the conventional timing of treatment as defined in the Cryotherapy for Retinopathy of Prematurity study. (19) The primary outcome of this study was visual outcome at 9 months' corrected age, with a secondary outcome being retinal structural outcome. A risk analysis model was used to select eyes for inclusion if the risk for adverse outcome was significant, and clinical characteristics were used to reclassify treatment-warranted ROP (TW-ROP) as type 1, for which treatment should be considered, or type 2 (eyes that should be followed and treated only if type 1 ROP develops). Type 1 ROP includes in zone 1, any ROP with plus disease or stage 3 ROP without plus disease, and in zone 2, stage 2 or 3 ROP with plus disease. The figure demonstrates examples of type I ROP in zone 1, and stage 3 ROP in zone 2 ( Figure) .
RETINOPATHY OF PREMATURITY SCREENING

Purpose of Screening
The goal of any ROP screening program is to detect visionthreatening ROP. ROP is a preventable cause of blindness, but timely diagnosis and treatment by an ophthalmologist with expertise in ROP is needed. Neonatologists and pediatricians play a critical role in the early care of premature infants, and should be aware of screening guidelines and risk factors for ROP. Structured registries and tracking systems are needed to ensure that all at-risk infants are screened and followed according to their ROP risk. Furthermore, regional variations in ROP presentation and risk exist, and screening guidelines that are regionally appropriate should be understood and implemented. (20) Guidelines for Screening
The joint guidelines for ROP screening in the United States were updated and published in 2013. (21) Infants born at less than or equal to 30 weeks' gestation or with birthweights of less than or equal to 1,500 g should be screened for ROP, as well as older or heavier newborns who have had a complicated medical course, at the discretion of the neonatologist. The timing of the first examination is based on the infant's gestational age at birth, so that the first examination is generally performed by 31 weeks for infants born at less than or equal to 27 weeks of gestation, and 4 weeks after birth for infants born at greater than or equal to 28 weeks of gestation. Guidelines for follow-up examinations are outlined to ensure that infants with ROP, particularly posterior (zone 1) ROP, or those with stage 2 or greater ROP, are seen in 1 week (or sooner) until the ROP regresses. ROP screening is typically performed at the bedside by an ophthalmologist with experience in ROP screening using indirect ophthalmoscopy.
As survival of premature infants increases around the world, differences in prenatal and available neonatal care can affect the susceptibility of these infants to, as well as the severity and course of, ROP. Due to differences in presentation time and neonatal care from one country to another, screening according to US guidelines might not be appropriate for detecting all infants at risk in middle income countries, so screening recommendations should be suited to the population. In developing countries, severe or rapidly progressive ROP may occur in older or heavier infants, so that routine screening cutoffs may be up to 34 weeks' gestational age at birth, and birthweight to 2,000 g, in addition to presence of various other medical or systemic diagnoses or exposures. For example, in India, further guidelines include screening for exposure to oxygen after 30 days, history of respiratory distress syndrome, sepsis, multiple blood transfusions, multiple births, apneic episodes, intraventricular hemorrhage, and in these cases, screening should be considered even for infants born at less than 37 weeks' gestation or less than 1,700 g birthweight. ROP screening practices ideally should be based on populationspecific data such as that available in India, (22) but determination and implementation of locally appropriate guidelines remains a struggle in some areas. The Table shows currently established country or regional guidelines, with many additional countries following either US or UK criteria (Table) .
Method of Screening
Although ROP screening should be performed by an ophthalmologist who is trained and experienced in ROP, digital imaging is becoming more common as an adjunct to the bedside examination or at times instead of the bedside examination. Several level 1 studies have shown the usefulness of digital imaging in screening for severe or referralwarranted ROP (RW-ROP). (23)(24)(25)(26)(27) Although digital images may not detect the presence of mild or peripheral ROP, there is a high sensitivity to detect ROP that meets type 1 treatment criteria. (28) A system must be in place for timely interpretation of such images. Follow-up imaging should probably occur more frequently (even weekly), with this understanding, and a plan for examination or treatment in place if significant ROP is detected. Digital imaging may also be useful for screening in underserved areas; however, a limitation for areas with limited resources is the cost of equipment needed to acquire goodquality retinal images. The e-ROP study further demonstrated that a telemedicine system using nonphysician imagers and nonphysician trained readers for detection of RW-ROP (defined as zone I disease, stage 3 disease or worse, or plus disease) is valid, safe, and cost-effective. (29) A secondary analysis of e-ROP data was performed to develop a predictive model for TW-ROP based on the trained readers' evaluation of digital wide-field retinal images taken at 34 weeks' postmenstrual age or earlier, along with gestational age and medical status, including respiratory support and the rate of weight at the first image session. The image evaluation findings of preplus disease, stage and zone of ROP, and presence of blot retinal hemorrhage at the first imaging session strongly predicted the development of TW-ROP, which may also be a useful indicator for identifying high-risk infants. (30) Additional screening tools have been developed, which take into account infant factors other than gestational age and birthweight. (31) The most common postnatal factor incorporated into ROP screening algorithms is a measure of postnatal weight gain, which is thought to act as a surrogate for overall infant medical status. Several algorithms have been developed, which similarly can provide additional information about risk of an infant developing significant ROP, or perhaps more importantly, the low risk for development of severe ROP in infants of higher gestational age, birthweight, and good (physiologic) postnatal weight gain. These algorithms can be a useful complement to the current ROP screening protocols, and can often identify at-risk infants very early in the postnatal course, often weeks before standard screening examinations. Because fewer than 10% of currently screened infants in the United States develop TW-ROP, the use of a screening tool that could identify an infant as low risk could potentially eliminate some examinations, which can be stressful, time-consuming, costly, and probably unnecessary. Although several of the postnatal weight gain algorithms have been validated in NICU populations in the United States and Canada, the sensitivity in other countries has varied. Screening after Discharge from the Neonatal Intensive Care Unit
Although the course of ROP is usually determined during the NICU stay, significant ROP can develop after discharge, and infants need to be followed until ROP regresses. The mean age of infants who received treatment in the ETROP trial for high-risk prethreshold ROP was 35.2 -2.3 weeks' postmenstrual age (range, 30.6-42.1 weeks) and 10.0 -2.0 weeks' chronologic age. Because of this variability, it is conceivable that an infant discharged early would require later treatment, though this is uncommon. Laser ablation of the peripheral avascular retina is standard therapy for ROP, though over the past few years, treatment with intravitreal injection of anti-VEGF agents has become more common, particularly for zone 1 or posterior zone 2 disease, or for aggressive posterior ROP. (33) Based on the mode of therapy, differences in disease regression and management have been seen, which affect ophthalmologic follow-up. With laser therapy, a response is seen within 1 to 2 weeks, and recurrences that require treatment are seen within a few weeks. With anti-VEGF therapy, disease regression is seen quickly, within days, but later recurrences can be seen, requiring monitoring of infants for the need to re-treat up to 70 weeks' postmenstrual age. Finally, other types of visual disability and ocular problems are found in the premature population, even in the absence of a history of significant ROP, (34) prompting continued ophthalmologic screening evaluations and management long after discharge from the NICU. Some of these problems are ocular, and others are associated with 
